You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBendroflumethiazide
Accession NumberDB00436  (APRD00666)
TypeSmall Molecule
GroupsApproved
Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

Structure
Thumb
Synonyms
SynonymLanguageCode
+--3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxideNot AvailableNot Available
6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxideNot AvailableNot Available
BendrofluazideNot AvailableIS
BendroflumethiazidGermanINN
BendrofluméthiazideFrenchINN
BendroflumethiazidumLatinINN
BendroflumetiazidaSpanishINN
BenzhydroflumethiazideNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
AprinoxSovereign Medical
CentylLEO Pharma
NaturetinNot Available
Neo-NaclexGlaxoSmithKline
SaluresPfizer
Brand mixtures
Brand NameIngredients
CorzideBendroflumethiazide + Nadolol
Neo-Naclex-KBendroflumethiazide and Potassium Chloride
PrestimBendroflumethiazide and Timolol
RauzideBendroflumethiazide + Rauwolfia serpentina
TensionormeBendroflumethiazide and Reserpine
TensofluxBendroflumethiazide and Amiloride
SaltsNot Available
Categories
CAS number73-48-3
WeightAverage: 421.415
Monoisotopic: 421.037781946
Chemical FormulaC15H14F3N3O4S2
InChI KeyHDWIHXWEUNVBIY-UHFFFAOYSA-N
InChI
InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
IUPAC Name
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Secondary aliphatic/aromatic amine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of high blood pressure and management of edema related to heart failure.
PharmacodynamicsBendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionAs a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
AbsorptionAbsorbed relatively rapidly after oral administration
Volume of distributionNot Available
Protein binding96%
MetabolismNot Available
Route of eliminationNot Available
Half life8.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bendroflumethiazide Action PathwayDrug actionSMP00090
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9643
Blood Brain Barrier-0.7807
Caco-2 permeable-0.7105
P-glycoprotein substrateNon-substrate0.6048
P-glycoprotein inhibitor INon-inhibitor0.7889
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8835
CYP450 2C9 substrateNon-substrate0.708
CYP450 2D6 substrateNon-substrate0.8398
CYP450 3A4 substrateNon-substrate0.6596
CYP450 1A2 substrateInhibitor0.8745
CYP450 2C9 substrateNon-inhibitor0.907
CYP450 2D6 substrateNon-inhibitor0.9351
CYP450 2C19 substrateNon-inhibitor0.9287
CYP450 3A4 substrateNon-inhibitor0.8607
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.8474
CarcinogenicityNon-carcinogens0.8156
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9858
hERG inhibition (predictor II)Non-inhibitor0.8967
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Bendroflumethiazide powder45.0USD g
Corzide 80-5 tablet4.29USD tablet
Corzide 40-5 mg tablet3.46USD tablet
Corzide 40-5 tablet3.35USD tablet
Corzide 80-5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point222-223 °CGoldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.
water solubility108 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.89BERTHOD,A ET AL. (1999)
logS-3.59ADME Research, USCD
pKa8.5SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.214 mg/mLALOGPS
logP1.83ALOGPS
logP1.7ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)9.04ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability36.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Goldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned
to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.

General ReferenceNot Available
External Links
ATC CodesC03AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
AcetylcholineBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
AlfentanilAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
AllopurinolThiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.
AlogliptinThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
AmifostineAntihypertensives may enhance the hypotensive effect of Amifostine.
AmiodaroneMay enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
BupivacaineBeta-Blockers may increase the serum concentration of Bupivacaine.
BuprenorphineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
ButabarbitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
ButethalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
ButorphanolAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
CanagliflozinThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
CarbacholBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
CarbamazepineThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
ChlorpropamideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
CodeineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
ColesevelamMay decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.
CyclophosphamideThiazide Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, granulocytopenia may be enhanced.
DiazoxideThiazide Diuretics may enhance the adverse/toxic effect of Diazoxide.
DihydrocodeineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
DipyridamoleMay enhance the bradycardic effect of Beta-Blockers.
DisopyramideMay enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.
DofetilideThiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.
DronedaroneMay enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.
DuloxetineHypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.
FentanylAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
FingolimodBeta-Blockers may enhance the bradycardic effect of Fingolimod.
FloctafenineMay enhance the adverse/toxic effect of Beta-Blockers.
GliclazideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
GlimepirideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
GliquidoneThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
GlyburideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
HeptabarbitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
HexobarbitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
HydrocodoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
HydromorphoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
Insulin AspartThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin DetemirThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlargineThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlulisineThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin LisproThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin RegularThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
Insulin, isophaneThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
LevorphanolAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
LinagliptinThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
LithiumThiazide Diuretics may decrease the excretion of Lithium.
MepivacaineBeta-Blockers may increase the serum concentration of Mepivacaine.
MetforminThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
MethacholineBeta-Blockers may enhance the adverse/toxic effect of Methacholine.
MethadoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
MethohexitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
MethylphenidateMay diminish the antihypertensive effect of Antihypertensives.
MidodrineBeta-Blockers may enhance the bradycardic effect of Midodrine.
MorphineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
NalbuphineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
ObinutuzumabAntihypertensives may enhance the hypotensive effect of Obinutuzumab.
OxcarbazepineThiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.
OxycodoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
OxymorphoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
PentobarbitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
PentoxifyllineMay enhance the hypotensive effect of Antihypertensives.
PethidineAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
PorfimerPhotosensitizing Agents may enhance the photosensitizing effect of Porfimer.
PrimidoneMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
RegorafenibMay enhance the bradycardic effect of Beta-Blockers.
RemifentanilAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
RepaglinideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
ReserpineMay enhance the hypotensive effect of Beta-Blockers.
RisperidoneHypotensive Agents may enhance the hypotensive effect of RisperiDONE.
RituximabAntihypertensives may enhance the hypotensive effect of RiTUXimab.
RivastigmineMay enhance the bradycardic effect of Beta-Blockers.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SaxagliptinThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
SecobarbitalMay enhance the orthostatic hypotensive effect of Thiazide Diuretics.
SufentanilAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TadalafilMay enhance the antihypertensive effect of Antihypertensives.
TapentadolAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
TolbutamideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
TopiramateThiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.
ToremifeneThiazide Diuretics may enhance the hypercalcemic effect of Toremifene.
TramadolAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
VardenafilMay enhance the antihypertensive effect of Antihypertensives.
VerteporfinPhotosensitizing Agents may enhance the photosensitizing effect of Verteporfin.
VildagliptinThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
YohimbineMay diminish the antihypertensive effect of Antihypertensives.
Food Interactions
  • Take with food to increase bioavailability.

Targets

1. Solute carrier family 12 member 3

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 12 member 3 P55017 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. Pubmed
  3. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK: Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73. Epub 2008 Jan 23. Pubmed

2. Calcium-activated potassium channel subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inducer

Components

Name UniProt ID Details
Calcium-activated potassium channel subunit alpha-1 Q12791 Details

References:

  1. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6. Pubmed

3. Carbonic anhydrase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Carbonic anhydrase 1 P00915 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Carbonic anhydrase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Carbonic anhydrase 2 P00918 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Carbonic anhydrase 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Carbonic anhydrase 4 P22748 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

Enzymes

1. Thiopurine S-methyltransferase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Thiopurine S-methyltransferase P51580 Details

References:

  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on March 31, 2014 13:39